These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36161830)

  • 1. Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension.
    Goldberg RA; Hill L; Davis T; Stoilov I
    BMJ Open Ophthalmol; 2022 Jul; 7(1):. PubMed ID: 36161830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies.
    Sun JK; Wang PW; Taylor S; Haskova Z
    Ophthalmology; 2019 May; 126(5):712-720. PubMed ID: 30419298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials.
    Wykoff CC; Elman MJ; Regillo CD; Ding B; Lu N; Stoilov I
    Ophthalmology; 2016 Aug; 123(8):1716-1721. PubMed ID: 27208982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
    Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
    Pieramici DJ; Wang PW; Ding B; Gune S
    Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis.
    Talcott KE; Valentim CCS; Hill L; Stoilov I; Singh RP
    Ophthalmol Retina; 2023 Jul; 7(7):605-611. PubMed ID: 36774994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
    Ip MS; Zhang J; Ehrlich JS
    Ophthalmology; 2017 May; 124(5):596-603. PubMed ID: 28284785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials.
    Bansal AS; Khurana RN; Wieland MR; Wang PW; Van Everen SA; Tuomi L
    Ophthalmology; 2015 Aug; 122(8):1573-9. PubMed ID: 26050541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.
    Bressler NM; Varma R; Mitchell P; Suñer IJ; Dolan C; Ward J; Ferreira A; Ehrlich JS; Turpcu A
    JAMA Ophthalmol; 2016 Feb; 134(2):160-6. PubMed ID: 26584450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
    Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
    Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
    Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
    Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
    JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
    Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
    Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
    Moshfeghi AA; Shapiro H; Lemmon LA; Gune S
    Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
    Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
    Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
    Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-Response to Ranibizumab: Improvement by 4 or More Steps in Diabetic Retinopathy Severity in Diabetic Retinopathy Clinical Research Network Protocol S.
    Chiang A; Garg SJ; Klufas MA; Ho AC; Hill L; Tsuboi M; Stoilov I
    Ophthalmol Retina; 2021 Mar; 5(3):251-260. PubMed ID: 32735903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy.
    Wykoff CC; Eichenbaum DA; Roth DB; Hill L; Fung AE; Haskova Z
    Ophthalmol Retina; 2018 Oct; 2(10):997-1009. PubMed ID: 31047503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema.
    Singh RP; Habbu K; Ehlers JP; Lansang MC; Hill L; Stoilov I
    Ophthalmology; 2016 Jul; 123(7):1581-7. PubMed ID: 27234930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.